XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > Significantly Undervalued and Strong Buy

<< Previous

Bullboard Posts

Next >>

Comment by Anklebiter42on Nov 12, 2021 10:00am

112 Views

Post# 34119203

RE:RE:Significantly Undervalued and Strong Buy

Hey KOkidneydisease. People need to do their own DD and stop expecting other people to do the heavy lifting. Not suggesting that about you. I know you have been around for a while. The reason why people panic when the price goes down in the short term is that they havent put the time into the research to have any confidence. Examples: Spacelab, Richmond and Moneyloser1.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China